Clinical Trials

28 trials
RecentStart dateEnrollment
Completed × Observational × Heart Failure × Clear all
NCT03098589 2025-03-30

Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL)

Celgene

Completed
1,149 enrolled
Head & NeckLymphoidOther hematologic neoplasm

Sleepiness, Arrhythmias, Cardiac, Cataract, Confusion, Coronary Artery Disease, Digestive System Diseases, Dizziness, Fatigue, Heart Failure, Hemorrhage, Hypersensitivity, Hypotension, Orthostatic, Hypothyroidism, Infections, Lymphoma, Peripheral Nervous System Diseases, Seizures, Thromboembolism, Tumor Lysis Syndrome, Neoplasms, Second Primary, Lung Diseases, Interstitial, Renal Insufficiency, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Teratogenesis

NCT01431326 2023-09-06

PTN_POPS

Duke University

Completed
3,520 enrolled
CNSClassical hematology

Healthcare-Associated Pneumonia, Pulmonary Arterial Hypertension, Schizophrenia, Treatment-Resistant, Adenoviridae Infections, Anxiety Disorders, Arrhythmias, Cardiac, Autistic Disorder, Bipolar Disorder, Bradycardia, Central Nervous System Infections, Endocarditis, Epilepsy, Headache, Heart Arrest, Heart Failure, Hemophilia A, Herpes Simplex, Hyperaldosteronism, Hypertension, Hypokalemia, Infections, Inflammation, Influenza, Human, Sleep Initiation and Maintenance Disorders, Meningitis, Menorrhagia, Migraine Disorders, Neutropenia, Pain, Pneumonia, Retinitis, Schizophrenia, Seizures, Spasm, Staphylococcal Infections, Urinary Tract Infections, Meningitis, Bacterial, Cytomegalovirus Retinitis, Hemangioma, Capillary, Sepsis, Renal Insufficiency, Chronic, Intraabdominal Infections

NCT02921828 2022-07-05

A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg

Celgene

Completed
1,149 enrolled
GenitourinaryPlasma cell

Sleepiness, Arrhythmias, Cardiac, Confusion, Consciousness Disorders, Dizziness, Fatigue, Heart Failure, Hypersensitivity, Infections, Jaundice, Liver Diseases, Multiple Myeloma, Peripheral Nervous System Diseases, Thromboembolism, Tumor Lysis Syndrome, Lung Diseases, Interstitial, Acute Kidney Injury, Teratogenesis

NCT02921802 2022-06-14

A Study of Special Use Results Surveillance of Revlimid 5mg Capsules

Celgene

Completed
4,626 enrolled
Classical hematologyMyeloidOtherPlasma cell

Arrhythmias, Cardiac, Constipation, Diarrhea, Heart Failure, Hemorrhage, Hypersensitivity, Infections, Multiple Myeloma, Myelodysplastic Syndromes, Myocardial Infarction, Neutropenia, Peripheral Nervous System Diseases, Thrombocytopenia, Tumor Lysis Syndrome, Lung Diseases, Interstitial, Renal Insufficiency, Venous Thromboembolism, Teratogenesis

NCT02922543 2022-06-14

A Safety and Efficacy Study of Revlimid® 5 mg Capsules in Patients With Relapsed or Refractory Multiple Myeloma Who Have Received Long-term Treatment With it Under the Actual Condition of Use

Celgene

Completed
361 enrolled
Classical hematologyOtherPlasma cell

Arrhythmias, Cardiac, Constipation, Diarrhea, Heart Failure, Hemorrhage, Hypersensitivity, Infections, Multiple Myeloma, Myocardial Infarction, Neutropenia, Peripheral Nervous System Diseases, Thrombocytopenia, Tumor Lysis Syndrome, Lung Diseases, Interstitial, Renal Insufficiency, Venous Thromboembolism, Teratogenesis

NCT03847753 2020-05-22

COMO-GMC

University of Aarhus

Completed
5,940,299 enrolled
Classical hematologyGenitourinaryHead & Neck

Acquired Immunodeficiency Syndrome, Anemia, Feeding and Eating Disorders, Atrial Fibrillation, Behavior, Mental Disorders, Connective Tissue Diseases, Diabetes Mellitus, Epilepsy, Gout, Hearing Disorders, Heart Failure, Hypersensitivity, Hypertension, Intellectual Disability, Migraine Disorders, Multiple Sclerosis, Neoplasms, Osteoporosis, Pain, Parkinson Disease, Prostatic Diseases, Schizophrenia, Somatoform Disorders, Thyroid Diseases, Vision Disorders, Inflammatory Bowel Diseases, Myocardial Ischemia, Mood Disorders, Substance-Related Disorders, Stroke, Dyslipidemias, Renal Insufficiency, Chronic